PALI
PALISADE BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.59
−6.47%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +86.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +235.3%
- EBITDA
- -66.1%
- EPS
- +50.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -16.3%
- EBIT
- -21.5%
- Net income
- -16.2%
- EPS
- +97.1%
- Free cash flow
- +11.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026